Investigational drug · Phase 3
Supportive care measures
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
5 still active
All registered trials
77
Any phase or sponsor naming "Supportive care measures"
First trial start
2023
May 16, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Supportive care measures", any sponsor or status.
Conditions studied
As listed on its trial records.
- Esophageal Squamous Cell Carcinoma
- Metastatic Urothelial Carcinoma
- Locally Advanced Urothelial Carcinoma
- Colorectal Cancer
- Pancreatic Ductal Adenocarcinoma
- Biliary Tract Cancer
- Gastroesophageal Cancer
- Non-small Cell Lung Cancer (NSCLC)
- Non-Muscle Invasive Bladder Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Pancreatic cancer · Bladder and urothelial cancer · Stomach and esophageal cancer · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Supportive care measures" as an intervention, largest first.
- PREVenting-ENvIronment-Reprotoxic Exposures Before In Vitro Fertilization (PREVENIR-FIV)Pivotal-lookingNot yet recruiting
Assistance Publique Hopitaux De MarseilleAcademic, hospital or other
NCT06100523 · 4,224 participants (planned) · Start Jan 2024 · Primary completion Jan 2026
Drug: hair sampling · For: Infertility
Sites: Marseille, France
- A Prospective Cohort Study on the Effect of Spinal Spinal Cord Injury on Sexual Function in Male PatientsActive, not recruiting
Peking University Third HospitalAcademic, hospital or other
NCT07093827 · 1,600 participants (planned) · Start Jan 1, 2020 · Primary completion Jan 31, 2030
Drug: Conservative management of ankylosing spondylitis; Conservative management of lumbar spinal stenosis · For: Sexual Function Abnormal; Spinal Cord Injuries (SCI)
Sites: Beijing, China
- Initial Oxygen Concentration at Birth in Late-Preterm InfantsPivotal-lookingNot yet recruiting
University of AlbertaAcademic, hospital or other
NCT07315594 · 1,520 participants (planned) · Start Nov 1, 2026 · Primary completion Jun 30, 2029
Drug: 60% Oxygen Group - Infants will start in 60% oxygen; 30% Oxygen Group - Infants will start in 30% oxygen · For: Preterm Birth
Sites: Edmonton, Canada
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06170788 · 614 participants (planned) · Start Dec 15, 2023 · Primary completion Jan 25, 2028
Drug: Sacituzumab tirumotecan; Pembrolizumab and 1 more · For: Non-small Cell Lung Cancer (NSCLC)
Sites: Phoenix, Arizona; Burbank, California; Grand Junction, Colorado · 220 sites in all
- Metabolism Informed Smoking Treatment: The MIST RCTPivotal-lookingCompleted
Vanderbilt-Ingram Cancer CenterAcademic, hospital or other
NCT04590404 · 606 participants · Start Nov 17, 2020 · Primary completion May 20, 2024
Drug: Nicotine Replacement Therapy; Varenicline · For: Smoking
Sites: Nashville, Tennessee
- Integrating a Stepped Care Model of Screening and Treatment for Depression Into Malawi's National HIV Care Delivery PlatformPivotal-lookingCompleted
RANDAcademic, hospital or other
NCT04777006 · 487 participants · Start Sep 1, 2021 · Primary completion Apr 30, 2023
Drug: Antidepressant Therapy · For: Depressive Disorder
Sites: Neno, Malawi
- An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain ServicePivotal-lookingNot yet recruiting
University of California, San FranciscoAcademic, hospital or other
NCT07296770 · 474 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 1, 2028
Drug: Pharmacologic Pain Management · For: Postsurgical Pain Management; Postsurgical Pain, Chronic; Opioid Use After Surgery
Sites: San Francisco, California
- A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06356311 · 473 participants · Start May 3, 2024 · Primary completion Oct 19, 2026
Drug: Sacituzumab tirumotecan; Trifluridine-Tipiracil and 5 more · For: Gastroesophageal Cancer
Sites: Gilbert, Arizona; Los Angeles, California; Orlando, Florida · 168 sites in all
- STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile InfectionPivotal-lookingNot yet recruiting
Medical University of WarsawAcademic, hospital or other
NCT07120490 · 424 participants (planned) · Start Oct 2025 · Primary completion Mar 31, 2027
Drug: Fidaxomicin; Vancomycin (VAN) treatment · For: Clostridioides Difficile Infection; Clostridioides Difficile Infection Recurrence; Fecal Microbiota Transplantation (FMT) and 3 more
- Efficacy of Lavender Essential Oil Chest Wraps in Infants With BronchiolitisPivotal-lookingRecruiting
University Hospital, GenevaAcademic, hospital or other
NCT06108648 · 400 participants (planned) · Start Dec 7, 2023 · Primary completion Mar 31, 2026
Drug: Lavender essential oil 10%, diluted in 90% olive oil · For: Bronchiolitis
Sites: Fribourg, Switzerland; Geneva, Switzerland
Newest research
PubMed records naming it or its code names, newest first.
- POEMS Syndrome: 2026 Update on Diagnosis, Risk-Stratification, and Management.
Dispenzieri A · Am J Hematol 2026
- Renal Outcomes Following Autologous Stem Cell Transplantation in Dialysis-Dependent Patients With Multiple Myeloma: A Single-Center Study From a Low- and Middle-Income Country.
Battat M, Khursani A, Alhendi MJ, et al. · Case Rep Hematol 2026
- Targeting the virus-host interface for the development of therapeutics against filoviruses.
Dupré J, Vickers MA, Groseth A, et al. · Curr Opin Virol 2026
- Autoimmune Oral Mucosal Diseases in Older Patients: An Overview of Early Recognition and Management in the Primary Care Setting.
Gupta A, Culton DA · Geriatrics (Basel) 2026
- Nuances of Perioperative Therapy in Gingivobuccal Cancers.
Nair AR, Ullattil PK, Thankappan K · Oral Maxillofac Surg Clin North Am 2026
- Refractory Pruritus in End-Stage Prostatic Adenocarcinoma: An Unusual Presentation of A Hypereosinophilic Syndrome.
Lorusso L, Bovello MV, Cavagna M, et al. · Eur J Case Rep Intern Med 2026
Also in development for Esophageal Squamous Cell Carcinoma
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
- Tegafur-gimeracil-oteracil potassiumS-1, tegafurPhase 38 trials
Ono Pharmaceutical Co., Ltd. · Gastric Cancer, Esophageal Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- H2 receptor antagonistPhase 34 trials
Merck & Co. · Lung Neoplasm Malignant, Esophageal Squamous Cell Carcinoma, Ovarian Cancer
- KC1036Phase 33 trials
Beijing Konruns Pharmaceutical Co., Ltd. · Ewing Sarcoma, Esophageal Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma (ESCC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.